Slide 1: Technology Solutions that Inform and Empower the Healthcare Community
Technology Solutions that Inform and Empower the Healthcare Community Corporate Presentation September 2026 The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without the written consent of OptimizeRx. A
Slide 2: Important Cautions Regarding Forward Looking Statements
Important Cautions Regarding Forward Looking Statements • This presentation has been prepared by OptimizeRx Corporation (“we,” “us,” “our,” “OptimizeRx” Instead, they are based only on our current beliefs, expectations and assumptions regarding the or the “Company”) and is made for informational p
Slide 3: At-a-Glance
At-a-Glance Leading technology provider for helping patients start and stay on therapy Corporate Profile Stock Information OptimizeRx enables engagement between life sciences Stock Price (as of 9/8/26) $7.60 organizations, physicians and patients Shares Outstanding OptimizeRx connects pharma with ph
Slide 4: Tackling Some Of Pharma's Toughest Commercial Challenges
Tackling Some Of Pharma’s Toughest Commercial Challenges BRAND VISIBILITY SHIFT TO SPECIALTY MEDICATIONS Crowded market 13% see strong HCP-DTC marketing alignment, Limited Face to Face time and only 16% think patients are well informed(2) DAILY EHR USE CAN BE ALL-CONSUMING AFFORDABILITY HCPs use EHR
Slide 5: Our Mission
Our Mission To combine human ingenuity, artificial intelligence, and technology to help life-science marketers evolve their approach, transform their customer relationships, and connect patients with the best possible treatments. 5 The content of this presentation is proprietary and confidential in
Slide 6: Growth Leaders | Growth Drivers
Growth Leaders | Growth Drivers EXPERIENCE EXPERIENCE 20+ Operations, Management, Sales, and Growing 20+ Senior Financial & Operational Roles Partner Networks STEVE SILVESTRO ED STELM AKH Chief Executive Officer Chief Financial & Strategic Officer EXPERIENCE EXPERIENCE EXPERIENCE 15+ Business 20+ Le
Slide 7: Technology that Connects the Healthcare Community
Technology that Connects the Healthcare Community PHARMA High ROI Connect to key customers Support brand market performance Reach into Top 20 Pharma ~400 Brands +2 MM +240 MM HCPs Patients PATIENTS Relevant treatment information +300 EHRs Productive care discussions HEALTHCARE PROFESSIONALS Navigati
Slide 8: AI-Enabled Platform Achieves Effective and Efficient Marketing Execution
AI-Enabled Platform Achieves Effective and Efficient Marketing Execution DIGITAL AUDIO / OOH* DIRECT MAIL / EMAIL* CTV / ATV / OTT* DAAP deals typically range DIGITAL DISPLAY* between ~$0.5M - $1.5 million SOCIAL* Dynamic Weekly DIGITAL POC DAAP Helps Deliver on Our Mission NPI Lists Our Dynamic Aud
Slide 9: Industry Programmatic Growth Opens Significant Whitespace
Industry Programmatic Growth Opens Significant Whitespace Positions OptimizeRx to capture incremental share of the multi-billion $ pharma Data digital ad market through new demand channels Providers • Unlocks access to the ~90% of U.S. digital display spend transacted Onboarders Agencies programmati
Slide 10: Driving Brand Demand Through AI-Driven Platform
Driving Brand Demand Through AI-Driven Platform CLIENT GOAL A brand sought to increase awareness among physicians treating newly diagnosed and relapsing rare disease patients. CLIENT CHALLENGES • Creating awareness among physicians likely to see patient population earlier in the patient journey-imme
Slide 11: Increasing Brand Touchpoints and Script Lift with Platform
Increasing Brand Touchpoints and Script Lift with Platform CLIENT GOAL Increase the number of oncology brand touchpoints by capitalizing on HCP social media presence. CLIENT CHALLENGES • Multi-indication therapy needed to keep suitability for numerous diseases top-of-mind. • Oncologists highly prese
Slide 12: Large, Under Penetrated Market With Tailwinds Driven by Increased Pharma Advertising Spend
Large, Under Penetrated Market With Tailwinds Driven by Increased Pharma Advertising Spend on Digital Channels 25.0 U.S. Pharma Digital Ad Spend ($ billions) 21.6 20.2 20.0 19.5 17.0 15.0 15.0 10.0 5.0 0.0 2022 2023 2024 2025 2026 Source: Leventhal, Rajiv. “Pharma Accounts for Nearly 90% of the Broa
Slide 13: Unique Capabilities of the Dynamic Audience Activation Platform (DAAP)
Unique Capabilities of the Dynamic Audience Activation Platform (DAAP) Accessible Market Opportunity for Combined Solution Set (HCP/DTC) ~350 Brands supported Current opportunity with with 45% coverage existing brands represents of the top 200 brands a $2B - $3B opportunity ~10% of brands utilize ~1
Slide 14: Key Performance Indicators
Key Performance Indicators Our footprint in the top 20 pharmaceutical manufacturers positions us well to compete and win our share of the largest category of addressable commercial spend Definition of Key Performance Indicators (KPIs) Trailing Twelve Months KPIs June 30, 2026 June 30, 2025 • Top 20
Slide 15: Strong Financial Momentum
Strong Financial Momentum $109 Q2 2026 RESULTS ANNUAL REVENUE GROWTH (millions) $95-$100 (E) $92 $20.5M Revenue $72 Fiscal 2026 guidance $61 $62 calls for revenue $(0.7)M between $95M and $100M with an GAAP Net $43 adjusted EBITDA Income between $21M and $25M. $25 $21 $4.9M $12 Adjusted EBITDA $7 $7
Slide 16: Key Takeaways
Key Takeaways HIGHLY SCALABLE PROVEN HEALTHCARE PLATFORM TECHNOLOGY LARGE & EXPANDING SUSTAINABLE MARKET OPPORTUNITY COMPETITIVE ADVANTAGE 16 The content of this presentation is proprietary and confidential information of OptimizeRx. It is not intended to be distributed to any third party without th
Slide 17: Reconciliation of GAAP to NON-GAAP Financial Measures
Reconciliation of GAAP to NON-GAAP FINANCIAL MEASURES (in thousands, except share and per share data, unaudited) • This presentation includes certain financial measures that are not prepared in accordance with generally accepted accounting principles (GAAP). These non- GAAP financial measures are pe